stockrow
Friday 6 November 2026
Export VSEE’s income statement to Excel — free account
VSee Health, Inc.
VSEE Healthcare Health Information Services
VSee Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.6 million, up 40.3% from fiscal 2024.
- Revenue
- −53.9%
- EPS
- +109.9%
- Free cash flow
- −257.6%
- Total debt
- +31.6%
Quarter to June 2026, against a year earlier
1.15
0.00
0.00%
Follow VSEE
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.70 | 0.52 | 0.83 | 0.49 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.38) | (3.92) | (4.88) | (5.29) | |
P/B ratio |
0.00 | 1.38 | 1.89 | 0.82 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.71 | 0.21 | 0.79 | 0.52 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.27) | (0.89) | (2.09) | (1.04) | |
EV/FCF |
(2.25) | (0.88) | (2.07) | (1.03) | |
Quick Ratio |
0.13 | 0.45 | 0.34 | 0.33 | |
Current Ratio |
0.16 | 0.52 | 0.41 | 0.40 | |
Net Debt/EBITDA |
(0.08) | 1.28 | 0.24 | (0.16) | |
Debt/Assets |
3.15% | 2.65% | 4.11% | 4.67% | |
Debt/Equity |
(0.11) | 0.11 | 0.12 | 0.10 | |
Asset Turnover |
0.66 | 0.69 | 0.75 | 0.72 | |
Operating CF/Net income |
2.60 | 0.25 | 0.94 | (1.39) | |
Capex/Depreciation |
(0.03) | (0.01) | (0.04) | 0.00 | |
Interest Coverage |
(2.72) | (3.75) | (26.30) | (33.42) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
103.77% | 176.92% | 132.03% | 185.90% | |
Intangible Assets out of Total Assets |
0.76 | 0.61 | 0.69 | 0.75 | |
Share Based Compensation of Revenue |
0.00% | 9.18% | 13.96% | 12.97% | |
Graham Net Nets |
(2.04) | (1.14) | (0.66) | (0.95) | |
Graham Number |
162.21 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(88.92%) | (195.10%) | (216.79%) | (393.09%) | |
Free Cash Flow Yield |
(44.94%) | (46.29%) | (46.07%) | (102.62%) | |
Revenue per Share |
19.24 | 15.59 | 5.28 | 2.33 | |
Operating CF per Share |
(3.65) | (7.65) | (4.10) | (1.75) | |
Capex per Share |
(0.11) | (0.03) | (0.04) | 0.00 | |
Free Cash Flow per Share |
(3.76) | (7.68) | (4.14) | (1.75) | |
Cash per Share |
2.29 | 20.06 | 2.25 | 0.68 | |
Shareholders Equity per Share |
(26.95) | 21.65 | 10.56 | 11.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(26.95) | 21.65 | 10.56 | 11.32 | |
Free Cash Flow |
(0.78) | (1.93) | (2.48) | (1.17) | |
Working Capital |
(19.70) | (7.88) | (6.95) | (4.83) | |
Capital Expenditures |
(0.02) | (0.01) | (0.03) | — | |
Net Current Asset Value |
(20.56) | (8.60) | (7.85) | (5.88) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.60 | 1.98 | 2.26 | 1.92 | |
Average Payables |
9.99 | 9.34 | 8.99 | 8.01 | |
Average Assets |
21.87 | 21.20 | 19.21 | 17.47 | |
Average Common Equity |
(0.41) | 2.72 | 1.41 | 0.93 |
Columns are period end dates · fundamentals updated 2 Nov 2026